- Lower pretreatment mean platelet volume (MPV) was an independent risk factor for poor survival in patients with inoperable stage III NSCLC who received concomitant chemoradiotherapy (CCRT).
Why this matters
- Although other studies have shown an association between low MPV and OS, this is the first in patients with locally advanced NSCLC.
- MPV is part of a routine blood panel and could be an easy way to identify the best candidates for CCRT.
- 115 patients with inoperable stage III NSCLC received CCRT with cisplatin plus etoposide.
- Funding: None disclosed.
- 65 patients had low pretreatment MPV (≤9 fL), and 50 had higher levels (>9 fL).
- Patients with MPV ≤9 fL had a significantly higher mean total platelet count (TPC; P=.005) and platelet distribution width (P=.027).
- Overall, median OS was significantly longer in patients with MPV >9.0 fL vs those with MPV ≤9.0 fL (45 vs 19 months; P<.001>
- OS was better with higher MPV regardless of stage or tumor histology.
- After multivariable analysis, independent factors of OS were MPV (HR, 0.807; P=.034), Eastern Cooperative Oncology Group Performance Status score (HR, 4.428; P<.001 and total platelet count p=".041).</li">
- Single-center, retrospective study.